LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis
暂无分享,去创建一个
N. Tinari | A. Ullrich | S. Iacobelli | F. Spinella | E. Piccolo | A. Cumashi | R. Lattanzio | M. Piantelli | C. Natoli | A. Bagnato | P. Stampolidis | D. Semeraro | M. D'egidio | S. Traini | R. Sorda | A. D. Risio | Imma Fichera | Pavlos Stampolidis | A. Risio
[1] Mingyong Han,et al. Tumor-derived vascular endothelial growth factor (VEGF)-a facilitates tumor metastasis through the VEGF-VEGFR1 signaling pathway. , 2011, International journal of oncology.
[2] Gerhard Christofori,et al. The angiogenic switch in carcinogenesis. , 2009, Seminars in cancer biology.
[3] Fu-Tong Liu,et al. Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response , 2009, The Journal of experimental medicine.
[4] F. Spinella,et al. Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade. , 2009, Cancer research.
[5] N. Tinari,et al. High expression of 90K (Mac‐2 BP) is associated with poor survival in node‐negative breast cancer patients not receiving adjuvant systemic therapies , 2009, International journal of cancer.
[6] N. Tinari,et al. Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. , 2006, Glycobiology.
[7] D. O’Rourke,et al. Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanism. , 2004, Molecular biology of the cell.
[8] Levon M Khachigian,et al. Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth , 2003, Nature Medicine.
[9] J. Parsons,et al. Focal adhesion kinase: the first ten years , 2003, Journal of Cell Science.
[10] Tae-Hee Lee,et al. Vascular Endothelial Growth Factor Modulates the Transendothelial Migration of MDA-MB-231 Breast Cancer Cells through Regulation of Brain Microvascular Endothelial Cell Permeability* , 2003, The Journal of Biological Chemistry.
[11] L. Strizzi,et al. Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patient survival , 2002, The Journal of pathology.
[12] A. Marchetti,et al. Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. , 2002, Cancer research.
[13] A. Bose,et al. A Phosphatidylinositol 3-Kinase-independent Insulin Signaling Pathway to N-WASP/Arp2/3/F-actin Required for GLUT4 Glucose Transporter Recycling* , 2002, The Journal of Biological Chemistry.
[14] N. Tinari,et al. Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. , 2000, Blood.
[15] G. Semenza,et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. , 2000, Cancer research.
[16] Rosato,et al. Differential effect on TCR:CD3 stimulation of a 90‐kD glycoprotein (gp90/Mac‐2BP), a member of the scavenger receptor cysteine‐rich domain protein family , 1998, Clinical and experimental immunology.
[17] R. Timpl,et al. Mac‐2 binding protein is a cell‐adhesive protein of the extracellular matrix which self‐assembles into ring‐like structures and binds β1 integrins, collagens and fibronectin , 1998, The EMBO journal.
[18] N. Tinari,et al. Identification of the tumor antigen 90K domains recognized by monoclonal antibodies SP2 and L3 and preparation and characterization of novel anti-90K monoclonal antibodies. , 1997, Biochemical and biophysical research communications.
[19] G. Neufeld,et al. Interleukin 6 Induces the Expression of Vascular Endothelial Growth Factor (*) , 1996, The Journal of Biological Chemistry.
[20] S. Barondes,et al. Galectins. Structure and function of a large family of animal lectins. , 1994, The Journal of biological chemistry.
[21] A. Ullrich,et al. The secreted tumor-associated antigen 90K is a potent immune stimulator. , 1994, The Journal of biological chemistry.
[22] P. Sismondi,et al. Prognostic value of a novel circulating serum 90K antigen in breast cancer. , 1994, British Journal of Cancer.
[23] S. Goldman,et al. The effect of epidermal growth factor on growth and differentiation of mouse preimplantation embryos in vitro. , 1993, Human reproduction.
[24] E. Taylor,et al. Cloning and characterization of a human Mac-2-binding protein, a new member of the superfamily defined by the macrophage scavenger receptor cysteine-rich domain. , 1993, The Journal of biological chemistry.
[25] Bing Li,et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.
[26] N. Weidner,et al. Localization of nuclear matrix proteins (NMPs) in multiple tissue types with NM-200.4 (an antibody strongly reactive with NMPs found in breast carcinoma). , 1991, The American journal of pathology.
[27] N. Ferrara,et al. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. , 1989, Biochemical and biophysical research communications.
[28] S. Iacobelli,et al. Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer. , 1986, Cancer research.
[29] J. Folkman. Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.
[30] J Folkman,et al. Transplacental carcinogenesis by stilbestrol. , 1971, The New England journal of medicine.
[31] S. Iacobelli,et al. Biological indicators of prognosis in Ewing's sarcoma: An emerging role for lectin galactoside‐binding soluble 3 binding protein (LGALS3BP) , 2010, International journal of cancer.
[32] W. Klohs,et al. Antiangiogenic agents. , 1999, Current opinion in biotechnology.